A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
135actual
Sites
39
Countries
Australia, Belgium, Canada +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-17 | actual | When the study began enrolling |
| Primary completion | 2025-05-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-28 | actual | The whole study's end, after follow-up |
| First posted | 2021-01-11 | actual | When this record first appeared on the registry |
| Results posted | 2026-06-17 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Extensive-stage Small Cell Lung Cancer
Interventions
- Biological: BMS-986012 — also filed as Fucosyl-GM1 Antibody
- Drug: Carboplatin
- Drug: Etoposide
- Biological: Nivolumab — also filed as BMS-936558
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Adverse Events
measured From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
Number of Participants With Serious Adverse Events
measured From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
Number of Participants With Adverse Events Leading to Discontinuation
measured From first dose to 100 days post last dose, or primary cutoff date, whichever occurs first (Up to approximately 43 months)
Number of Participants Who Died
measured From first dose to primary cutoff date (Up to approximately 43 months)
Progression Free Survival (PFS) Per Blinded Independent Central Review (BICR)
measured From randomization to the date of the first documented tumor progression, or death, or primary cutoff date, whichever occurs first (Up to approximately 50 months)
Posted documents
hosted by the registry — we link, never re-serveStudy Protocol and Statistical Analysis Planposted 2023-03-22 · 9.5 MB · Prot_SAP_000.pdf
Publications
- PMID 36275912 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed